MARKET NEWS AND UPDATES.
Get notified for Latest News and Market Alerts.
Get notified for Latest News and Market Alerts.
×
The proceeds from sales of these assets will be used for repayment of Bank Loans.
The company has managed to continue its operations as and when restrictions have been eased particularly for Pharmaceuticals as essenti
Nectar Lifesciences Ltd has posted a net profit of Rs 16.11 crore for the quarter ended September 30, 2016 as compared to Rs 12.30 cror
The total income for the quarter was at Rs.397.3 crore as against Rs.444.4 Cr (YoY).
The company has appointed Ms. Guljit Chaudhri as an Additional Independent Director of the Company with effect from December 29, 2015.
For Q2, the total income stands at Rs. 396.7 Cr as against Rs. 393.9 Cr (YoY).
The total income was at Rs.407.7 Crore.
The company has filed 15 ANDAs in United States and out of which eight have been reviewed inclusive of Baddi facility of formulations w
Report said that the company have Regulatory approvals for majority of Plants.
The facility is already approved by various international regulatory agencies such as US-FDA, MCC South Africa, PMDA Japan, OGYI-Hung
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
